🇺🇸 FDA
Pipeline program

Protexia

QOPK 4439

Phase 1 mab completed

Quick answer

Protexia for Intervention for Nerve Agent Exposure is a Phase 1 program (mab) at UNITED THERAPEUTICS Corp with 1 ClinicalTrials.gov record(s).

Program details

Company
UNITED THERAPEUTICS Corp
Indication
Intervention for Nerve Agent Exposure
Phase
Phase 1
Modality
mab
Status
completed

Clinical trials